IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL. (12th June 2019)

Record Type:: Journal Article
Title:: IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL. (12th June 2019)
Main Title:: IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL
Authors:: Brown, J.R.
Chan, R.J.
Xing, G.
Bhargava, P.
Ruzicka, B.
O'Brien, S.M.
Abstract:
Is Part Of:: Hematological oncology. Volume 37(2019)Supplement 2
Journal:: Hematological oncology
Issue:: Volume 37(2019)Supplement 2
Issue Display:: Volume 37, Issue 2 (2019)
Year:: 2019
Volume:: 37
Issue:: 2
Issue Sort Value:: 2019-0037-0002-0000
Page Start:: 385
Page End:: 386
Publication Date:: 2019-06-12
Subjects:: Hematological oncology -- Periodicals
Hematology
Medical Oncology
616.99418005
Journal URLs:: http://onlinelibrary.wiley.com/ ↗
DOI:: 10.1002/hon.55_2631 ↗
Languages:: English
ISSNs:: 0278-0232
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 4291.550000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 12428.xml